46 results on '"Mason, Stephen W."'
Search Results
2. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
3. Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B
4. Discovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid Complexes
5. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
6. Discovery and Structural Characterization of a New Inhibitor Series of HIV-1 Nucleocapsid Function: NMR Solution Structure Determination of a Ternary Complex Involving a 2:1 Inhibitor/NC Stoichiometry
7. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
8. An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19
9. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
10. Modified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B
11. AVIDIO as a novel oncolytic immunotherapy platform for the treatment of colorectal cancer.
12. Cloning and functional characterization of PTRF, a novel protein which induces dissociation of paused ternary transcription complexes
13. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
14. Identification of a transcript release activity acting on ternary transcription complexes containing murine RNA polymerase I
15. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor
16. Transcriptional antitermination
17. Gene Expression and the Cell Cycle: A Family Affair
18. Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART
19. Virus-like vesicles expressing multiple antigens for immunotherapy of chronic hepatitis B
20. The Modeling of Shock-Wave Pressures, Energies, and Temperatures Within the Human Brain Due to Improvised Explosive Devices (IEDs) Using the Transport and Burgers' Equations
21. Adoption of the Transport and Burgers' Equations in Modeling Neurological Shock-Waves in the Human Brain Due to Improvised Explosive Devices (IEDs)
22. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection
23. Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs
24. Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART.
25. Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold
26. Resistance Studies with HIV-1 Non-Catalytic Site Integrase Inhibitors Introduction
27. Identification of BI-C, a Novel HIV-1 Non-Catalytic Site Integrase Inhibitor
28. Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV
29. Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein
30. Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
31. A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallizationviacompound-mediated dimerization
32. Novel Inhibitor Binding Site Discovery on HIV-1 Capsid N-Terminal Domain by NMR and X-ray Crystallography
33. Inside Cover: Monitoring Binding of HIV-1 Capsid Assembly Inhibitors Using19F Ligand-and15N Protein-Based NMR and X-ray Crystallography: Early Hit Validation of a Benzodiazepine Series (ChemMedChem 3/2013)
34. Monitoring Binding of HIV-1 Capsid Assembly Inhibitors Using19F Ligand-and15N Protein-Based NMR and X-ray Crystallography: Early Hit Validation of a Benzodiazepine Series
35. Inhibitors of Respiratory Syncytial Virus Replication Target Cotranscriptional mRNA Guanylylation by Viral RNA-Dependent RNA Polymerase
36. Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein
37. Inhibitors of Respiratory Syncytial Virus Replication Target Cotranscriptional mRNA Guanylylation by Viral RNA-Dependent RNA Polymerase
38. Interaction between Human Respiratory Syncytial Virus (RSV) M2-1 and P Proteins Is Required for Reconstitution of M2-1-Dependent RSV Minigenome Activity
39. RNA polymerase I transcription termination: similar mechanisms are employed by yeast and mammals 1 1Edited by M. Yaniv
40. A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization.
41. Monitoring Binding of HIV-1 Capsid Assembly Inhibitors Using 19F Ligand-and 15N Protein-Based NMR and X-ray Crystallography: Early Hit Validation of a Benzodiazepine Series.
42. Direct interaction between two Escherichia coli transcription antitermination factors, NusB and ribosomal protein S10
43. The Amino-Terminal Domain of the Transcription Termination Factor TTF-I Causes Protein Oligomerization and Inhibition of DNA Binding.
44. RNA polymerase I transcription termination: similar mechanisms are employed by yeast and mammals11Edited by M. Yaniv
45. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19.
46. Monitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine series.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.